Global Pharma companies in an effort to control R&D costs and increase efficiency are increasingly outsourcing their R&D projects. India with skilled workforce at a competitive cost stands to benefit from this trend. The Inflation Reduction Act should also help demand along with prevailing China +1 strategy. The R&D pipeline sees biologics/large molecules outpacing small molecules since FY18.
Rising trend of R&D expenditure in pharma
India with skilled workforce at a competitive cost stands to benefit from this trend
Published on
December 11, 2024 06:32
Tags
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.
You are reading {{data.cm.views}} out of {{data.cm.maxViews}} free articles.
This is your last free article.